Objective. The efficacy and safety of oral lubiprostone for relieving symptoms of opioid-induced constipation (OIC) in patients with chronic noncancer pain were evaluated in a randomized, double-blind, placebo-controlled study. These data were also pooled with those from two similar phase 3 studies to explore the effects of methadone on treatment response.
Methods. In the primary study, adults with OIC (fewer than three spontaneous bowel movements [SBMs] per week) were randomized to receive lubiprostone 24 mcg or placebo twice daily for 12 weeks. The primary end point was a change from baseline in the frequency of SBMs at week 8 in patients without a prior dose reduction. For the pooled analysis, the efficacy of lubiprostone was compared with placebo in patients receiving methadone or nonmethadone opioids. Responders were defined as patients with nine or more weeks of nonmissing SBM data who had one or more additional SBMs per week from baseline for each week that data were available and three or more SBMs per week for nine or more weeks.
Results. In the primary study, the change from baseline at week 8 in SBM frequency was similar in V C 2017 American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com the lubiprostone and placebo groups (P 5 0.842). In the pooled analysis, the response rate was significantly higher with lubiprostone treatment vs placebo for patients receiving nonmethadone opioids (P 5 0.002) but was similar between lubiprostone treatment and placebo in patients receiving methadone (P 5 0.692). The safety profile of lubiprostone was unaffected by methadone use.
Conclusions. The phase 3 study did not meet its primary efficacy end point. However, analysis of pooled data from all phase 3 studies in the OIC clinical development program, stratified by methadone opioid usage, confirmed that lubiprostone is effective for treatment of OIC in patients taking nonmethadone opioids; no safety concerns were identified based on the type of opioid used.
Introduction
Chronic pain affects an estimated 31% of adults in the United States [1] , and when severe, opioids are commonly used for its treatment. The effectiveness of chronic opioid treatment for pain is often limited by side effects. Constipation is one of the most common side effects, with 40% of opioid-treated patients reporting fewer than three complete bowel movements (BMs) per week [2] . A reduction or cessation in the use of opioids to make BMs less difficult was reported by 33% of patients, resulting in higher pain levels in 92% of these patients [3] .
Lubiprostone, an activator of C1C-2 chloride channels [4] , was approved by the US Food and Drug Administration (FDA) for the treatment of opioid-induced constipation (OIC) in adults with chronic noncancer pain [5] . In a randomized, double-blind, placebo-controlled phase 3 study in patients with OIC, lubiprostone (24 mcg twice daily [BID] ) significantly increased the frequency of spontaneous bowel movements (SBMs) compared with placebo (3.3 vs 2.4 SBMs/week). Additionally, the percentage of patients with their first SBM within 24 or 48 hours of receiving the initial dose of lubiprostone was significantly greater compared with patients receiving placebo [6] .
In preclinical models, lubiprostone reversed morphineinduced inhibition of chloride secretion in a concentrationdependent manner and reversed morphine-induced constipation effects in mice [7] . In contrast to the effect of lubiprostone on morphine-inhibited chloride secretion, methadone dose-dependently and significantly inhibited the stimulation of C1C-2 chloride currents by lubiprostone in a naloxone-independent (i.e., nonopioid) manner [8] .
The clinical consequences of methadone on the inhibition of chloride secretion induced by lubiprostone are unclear but may in part be responsible for the fact that patients receiving methadone showed a lower SBM response to treatment with lubiprostone than patients treated with other opioid agonists when a post hoc subgroup analysis (based on the chemical class of opioids) of three separate clinical trials with lubiprostone was performed [9] .
The objectives here are 1) to report the results of a phase 3 study of the treatment of patients with OIC with lubiprostone or placebo and 2) to place these results in context by evaluating the efficacy of lubiprostone vs placebo in patients treated with methadone vs the observed efficacy in those patients treated with other opioids. To accomplish the second objective, data from the randomized study reported here were pooled with data from two similar pivotal phase 3 clinical studies in patients with OIC who received lubiprostone 24 mcg BID or placebo for 12 weeks. The data were analyzed according to whether patients received methadone or nonmethadone opioids. The individual results of the other two pivotal trials have been previously reported [6, 10] .
Methods

Phase 3 Study in Patients with OIC Treated with Lubiprostone or Placebo
Patients
The inclusion and exclusion criteria for this study were similar to those used in the pivotal phase 3 study for lubiprostone previously described by Cryer et al. [6] . Men and nonpregnant, nonlactating women age 18 years or older were eligible to enroll in this study. Key inclusion criteria for the current study included consistent treatment for chronic noncancer pain with any full agonist opioid for 30 or more days prior to screening and continued opioid therapy for the duration of the study. Patients also had to have OIC, defined as having an average of fewer than three SBMs per week and one or more of the following for 25% or more of SBMs during each week of the screening period: hard or very hard stool, sensation of incomplete evacuation, and moderate to very severe straining. Concomitant medications affecting gastrointestinal motility (other than opioid agonist therapy), including stool softeners and laxatives, had to be discontinued from the screening visit until the completion of the study. However, the use of certain rescue medications to relieve constipation was allowed at investigator discretion, subject to protocol rules.
Key exclusion criteria included receipt of opioid therapy for cancer-related pain (because lubiprostone is not indicated for this patient population) [5] , abdominal pain, scleroderma, and/or for the management of drug addiction. Because abdominal pain due to non-OIC etiologies and gastrointestinal symptoms commonly observed in patients with scleroderma could have potentially introduced confounders that would have compromised the studies, these patient populations were excluded. Patients were also excluded if there were changes to their opioid treatment (i.e., medication, dosage, or route of administration) within 30 days of screening or if they were likely to discontinue or adjust the dosage by 30% or more over the course of the study. Patients with anatomic or organic bowel disorders, constipation not resulting from opioid use (based on investigator judgment), or who had gastrointestinal/abdominal surgery in the 90 days before screening were also ineligible for the study.
Study Design and Treatment
This randomized, double-blind, placebo-controlled phase 3 study (NCT00597428) was conducted at 88 investigative sites (84 in the United States and four in Canada) between August 6, 2007, and March 6, 2009 . The study protocol and procedures were approved by institutional review boards at each center and were conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. All participants provided written informed consent prior to enrollment in the study.
The study design and treatment protocol were essentially identical to those reported by Cryer et al. [6] . Briefly, after a three-week screening period, patients meeting the eligibility requirements were randomized in a 1:1 ratio to oral lubiprostone (24 mcg BID; total daily dose 48 mcg) or matching placebo capsules for 12 weeks. The treatment for each patient was assigned through interactive response technology (IRT). Following the baseline visit, patients received telephone assessments at weeks 1, 6, and 10 of the study and returned to the clinic for visit assessments at weeks 4, 8, and 12. A safety follow-up visit to the clinic was performed at week 14.
Efficacy Assessments
The primary efficacy end point was the change from baseline in frequency of SBMs at week 8 of treatment for patients without a dose reduction, as determined by the patients' responses to the daily electronic diary questions. Key secondary efficacy end points included change in the frequency of SBMs at week 12 and overall, change in the percentage of patients with an SBM within 24 and 48 hours of the first dose, and patientreported changes in the following constipation-related symptoms and signs: straining associated with SBMs, stool consistency, constipation severity, abdominal bloating and discomfort, and bowel habit regularity.
Safety Assessments
Investigators assessed the frequency and intensity of reported adverse events (AEs). AEs were recorded from the day of the first dose of study medication until two weeks after the last dose. AEs were recorded and classified by investigators using preferred terms from the Medical Dictionary for Regulatory Activities, version 13.1. Other safety assessments included physical examination, monitoring of vital signs, and laboratory analysis of blood and urine samples at scheduled clinic visits. In addition, patients evaluated nausea using the modified Functional Living Index-Emesis (MFLIE) and pain using the Brief Pain Inventory short form (BPI-SF) as part of diary entries.
Statistical Analysis
The primary end point in this study was the change from baseline in SBM frequency at week 8; this evaluation only included patients who did not have a dose reduction before week 8. An analysis of covariance was used to compare the mean change in SBM frequency between treatment groups. Wilcoxon signed-rank tests or pairwise t tests were performed to assess overall improvement from baseline in constipation-related symptoms and signs.
Power analysis indicated that a sample size of 130 patients per treatment group would provide 93% or more statistical power for the detection of an average change in SBM frequency of 1.5 (SD ¼ 3.5) compared with placebo at week 8. To account for patients who would drop out or who would require a dose reduction, 420 patients (210 per treatment group) were required.
The intent-to-treat (ITT) population, which included all randomized patients who received one or more doses of double-blind study medication and provided one or more treatment period diary entries, was used for the efficacy analyses. All randomized patients who took one or more doses of study medication were included in the safety analyses. Patient demographic data were summarized by treatment group and overall using descriptive statistics; the comparability of treatment groups was assessed with a one-way analysis of variance for continuous variables and a chi-square test for categorical variables.
Pooled Study Analyses
Pooled Studies and Patients
Data were pooled from three randomized, double-blind, placebo-controlled, 12-week phase 3 studies (NCT01298219 [10] , NCT00595946 [6] , NCT00597428 [current study]) in patients with OIC who were randomized to treatment with lubiprostone 24 mcg BID or placebo. Pooling the results of the three studies based on the opioid chemical class increased the sample sizes for the post hoc subgroup analyses, thus increasing the statistical power. The patients from the pooled studies were divided into two groups for the post hoc analyses of their response to lubiprostone. One group comprised patients on methadone (including those using propoxyphene, a congener of methadone), and the second group (nonmethadone) consisted of patients using opioids other than methadone.
Efficacy End Points
Patients were defined as overall responders if they had one or more additional SBMs per week for each week that data were available, compared with baseline, and if they had three or more SBMs per week for nine or more weeks. This responder definition was used for the primary end point in one of the phase 3 trials with lubiprostone [10] and was applied post hoc to the data presented here. The mean changes from baseline for straining associated with SBMs, stool consistency, constipation severity, abdominal bloating, and abdominal discomfort were examined as prespecified secondary efficacy end points.
Efficacy and safety were analyzed separately in patients receiving methadone or nonmethadone opioids. Patients taking methadone were included in the methadone analysis group, regardless of whether they were taking nonmethadone opioids concurrently.
Results
Phase 3 Study in Patients with OIC Treated with Lubiprostone or Placebo
Patients
A total of 451 patients were enrolled and randomized; 14 patients did not receive study treatment (Supplementary Figure 1) . For the safety population, 213 patients were randomized to receive placebo and 224 were randomized to receive lubiprostone. One patient from each treatment group was excluded from the ITT population because no postbaseline data were reported; therefore, the ITT population consisted of 212 patients in the placebo group and 223 in the lubiprostone group. A total of 305 patients (67.6%) completed the study. The discontinuation rates were comparable between the two treatment groups; the most frequent reasons for discontinuation were patient choice (8.6%), lost to follow-up (5.3%), and AEs (3.1%).
Demographic and baseline disease characteristics were comparable between the ITT patients in the two treatment groups (Table 1 ). The mean age was 49.4 years (SD ¼ 10.1 years). A total of 61.1% of the patient population was female, and 87.3% was white. Patients reported a mean of 1.6 SBMs per week (SD ¼ 1.3 SBMs/week) at study entry. The most commonly used opioids were oxycodone, methadone, morphine, and hydrocodone. A total of 77 patients (17.7%) were receiving methadone, 38 randomized to placebo and 39 randomized to lubiprostone. Mean (SD) morphine-equivalent daily doses (MEDDs) at baseline in patients randomized to placebo and lubiprostone were 787 (6593) mg and 373 (787) mg, respectively. One patient randomized to placebo who received 95,400 mg MEDD of transdermal fentanyl citrate is the primary reason for the difference in MEDD between the two treatment groups.
Spontaneous Bowel Movements
Irrespective of the specific opioid treatment, the mean change in the frequency of SBMs at week 8 compared with baseline (the primary study end point) was not statistically significantly different in patients treated with lubiprostone compared with placebo (P ¼ 0.842) in the ITT population, and no statistically significant differences were noted at week 12 or overall (Figure 1) . The number of patients who experienced an SBM within 24 or 48 hours of receiving the first dose of study medication did not statistically significantly differ (P ¼ 0.502) between the lubiprostone and placebo treatment groups: 33.2% and 30.2% of patients treated with lubiprostone and placebo, respectively, reported an SBM within 24 hours, and 61.0% and 55.7% of patients reported an SBM within 48 hours.
Nonmethadone-treated patients who received lubiprostone had a numerically greater increase from baseline in SBM frequency at week 8 compared with patients receiving placebo (3.0 vs 2.5 SBMs/week; P ¼ 0.484). Further, when analyzing only data from patients with fewer than three SBMs per week at baseline who were taking nonmethadone opioids, a significant increase in the change in frequency of SBMs from baseline was observed in patients receiving lubiprostone vs placebo (2.9 vs 2.4 SBMs/week; P ¼ 0.0480). Although statistically significant, this difference in the change in frequency of SBMs from baseline between patients receiving lubiprostone vs placebo is likely not clinically significant.
Constipation-Related Symptoms
There were statistically significant differences between treatment groups for changes from baseline in straining associated with SBMs (À0.8 vs À0.5; P ¼ 0.010) and abdominal discomfort (À0.5 vs À0.4; P ¼ 0.027) (Figure 2 ). Differences from baseline for stool consistency, constipation severity, and abdominal bloating were numerically greater, but not statistically significantly different, in patients treated with lubiprostone compared with those receiving placebo (Figure 2 ).
Safety
Of the 437 patients who received one or more doses of study medication, 233 patients (53.3%) reported one or more AEs. The number and percentage of patients reporting AEs were similar between patients receiving lubiprostone and placebo ( Table 2 ). The most frequent AEs were nausea, diarrhea, and flatulence. Overall, 113 patients (25.9%) reported one or more treatment-related AEs; although a greater proportion of patients treated with lubiprostone (22.4%) reported gastrointestinal treatment-related AEs compared with patients in the placebo group (16.4%), the difference was not statistically significant (P ¼ 0.117).
A total of 14 patients (3.2%) reported one or more serious AEs (SAEs); the number of patients was equal in each treatment group. In the lubiprostone treatment group, the following SAEs were each reported by a single patient: intestinal obstruction, pneumonia, herpes zoster, multiple sclerosis relapse, migraine, and cholecystitis; one patient experienced irritable bowel syndrome and delayed gastric emptying. In the placebo group, the following SAEs were each reported by a single patient: fecaloma, upper abdominal pain, diverticulitis, tricuspid valve disease, angina pectoris, chronic obstructive pulmonary disease, and hypersensitivity; one patient experienced pyrexia, chills, malaise, and confusion. All SAEs except one were considered unrelated to study medication by the investigators. The only SAE There were no deaths during the study.
Changes from baseline in MFLIE scores were similar at each month for the lubiprostone and placebo groups (P ! 0.132), indicating that average changes in nausea severity were comparable in the two arms. Likewise, changes from baseline in scores for every BPI-SF domain were similar at each month in patients who received lubiprostone or placebo (P ! 0.082).
Pooled Study Analyses
Pooled Studies and Patients
To further analyze the effects of methadone on the safety and efficacy of lubiprostone, and to place the current study into context, a pooled analysis of all three randomized, double-blind, placebo-controlled phase 3 studies comprising the lubiprostone development program for OIC was conducted. For the pooled analysis, data from this study were combined with data from the other two pivotal randomized, double-blind, placebocontrolled phase 3 studies; NCT01298219 (10) reported by Jamal et al. and NCT00595946 reported by Cryer et al. (Figure 3 ) [6] . Patients who were receiving methadone were excluded from the study by Jamal et al. [10] . In the Cryer et al. study, 19.3% of patients were receiving methadone, 35 were randomized to placebo, and 45 were randomized to lubiprostone [6] . As noted above, in the current study, 17.7% (38 randomized to placebo, 39 randomized to lubiprostone) were receiving methadone. The pooled ITT population included 1,272 patients (nonmethadone opioids, N ¼ 1,115; methadone, N ¼ 157), and the pooled safety population included 1,275 patients (nonmethadone opioids, N ¼ 1,118; methadone, N ¼ 157). The methadone group also included 19 patients receiving propoxyphene. Baseline demographic and clinical characteristics were mostly similar between patients receiving lubiprostone or placebo in the nonmethadone opioid and methadone groups in the pooled ITT population (Table 3 ). In the study reported by Cryer et al. [6] , patients randomized to placebo and lubiprostone had a baseline MEDD of 237 mg (451 mg) and 265 mg (407 mg), respectively. In the study reported by Jamal et al., patients randomized to placebo and lubiprostone had a baseline MEDD of 99 mg (120 mg) and 130 mg (227 mg) [10] .
Efficacy
Among patients receiving nonmethadone opioids, a statistically significantly higher proportion in the lubiprostone treatment group met response criteria compared with those who received placebo (P ¼ 0.002) (Figure 4) . No statistically significant differences in response rate were observed between treatment groups for the 157 patients who received methadone (P ¼ 0.692). An analysis of secondary end points found that in patients who received nonmethadone opioids, treatment with lubiprostone resulted in improvements from baseline in constipation-associated symptoms (i.e., straining, stool consistency, constipation severity, abdominal bloating, and abdominal discomfort) that were statistically significantly greater than the improvements noted in patients receiving placebo (P 0.015) ( Figure 5 ). Among patients who used methadone, no statistically significant differences in these end points were observed between the lubiprostone treatment group and the placebo group.
Safety
Adverse events from the pooled analysis are shown in Table 4 . Among patients treated with lubiprostone, the incidence of AEs was similar in the nonmethadone opioid group (57.0%) and the methadone group (57.6%). Treatment-related AEs also occurred with similar incidences in patients treated with lubiprostone who were receiving nonmethadone opioids (31.2%) and methadone (30.6%). SAEs were rare in patients receiving methadone; no SAEs were considered related to lubiprostone in any analysis group. AEs that led to discontinuation appeared to occur with comparable incidence regardless of the class of opioids. In all groups, gastrointestinal-related events were the types of AEs most often reported by patients. The most common AEs (!3% of patients in any group) included nausea, diarrhea, flatulence, and vomiting.
Discussion
This randomized, double-blind, placebo-controlled study of lubiprostone for the treatment of OIC in patients with chronic noncancer pain did not meet the primary efficacy end point (change from baseline in frequency of SBMs at week 8 for patients without a dose reduction). This contrasts with the results of the similarly designed and conducted study reported by Cryer et al., which demonstrated that lubiprostone 24 mcg BID statistically significantly increased the frequency of SBMs compared with placebo (P ¼ 0.005) [6] .
Two differences have been identified between the patient populations of the current study and the Cryer et al. study. First, among patients in both studies with three or more SBMs per week at baseline (these patients were erroneously included; they did not meet the entry criterion of having an average of fewer than three SBMs per week), there were more patients with three or more SBMs per week at baseline in the current study (N ¼ 46, 25 who received lubiprostone and 21 who received placebo) than in the study by Cryer et al., which met its primary end point (N ¼ 26, 16 who received lubiprostone and 10 who received placebo). Second, although the proportion of patients taking methadone was similar in both studies, the MEDD of methadone was 32% greater in the current study compared with the study that met its efficacy end point. Regression analysis has revealed a MEDDdependent trend in the methadone effect on impairing the efficacy of lubiprostone [11] . Further, these findings are consistent with the lubiprostone prescribing information and with preclinical data reported by Cuppoletti et al., who found that methadone, in a concentration-dependent manner, reduced activation (maximum inhibition of 83.1%) of C1C-2 chloride channels, the molecular target of lubiprostone, in cultured T84 intestinal cells [8] . As noted in the Results section, an analysis from the current study that included only patients with fewer than three SBMs per week at baseline who were receiving nonmethadone opioids found a significant increase with lubiprostone vs placebo in the change in frequency of SBMs from baseline.
Following the in vitro findings that methadone inhibits lubiprostone stimulation of C1C-2 chloride currents [8] , another randomized, double-blind, placebo-controlled study of lubiprostone for the treatment of OIC in patients with chronic noncancer pain was conducted, which excluded patients receiving methadone [10] . This study, reported by Jamal et al., found a statistically significantly higher (P ¼ 0.030) percentage of overall SBM responders with lubiprostone treatment (27.1%; 58/214 patients) compared with placebo (18.9%; 41/217 patients) [10] . These findings and the analysis herein of pooled data from all three phase 3 studies in the OIC clinical development program for lubiprostone, stratified by methadone opioid usage, confirm the clinical efficacy of lubiprostone in patients taking nonmethadone opioids.
The overall safety profile and lack of interference of lubiprostone on the analgesic effects of opioids observed in the current study are consistent with the results from similarly designed studies of lubiprostone [6, 10] . Further, analysis of the pooled data found that the use of (NCT00595946) 1°EP=Δ from BL in SBM frequency at week 8 Figure 3 Study design and descriptions of three phase 3 studies of lubiprostone 24 mcg BID for opioid-induced constipation (intent-to-treat populations). *Per protocol, patients who were receiving methadone were excluded from the study. † Thirty-four patients in the placebo group and 46 in the lubiprostone group were receiving methadone. ‡ Thirty-eight patients in the placebo group and 39 in the lubiprostone group were receiving methadone. BID ¼ twice daily; BL ¼ baseline; EP ¼ end point.
Table 3
Baseline demographic and clinical characteristics by usage of nonmethadone opioids or methadone in the pooled intent-to-treat population methadone did not appear to affect the pattern of AEs observed with lubiprostone, suggesting that this class of opioids does not alter the safety profile of lubiprostone.
A strength of the pooled analysis was that, given the relatively small number of patients who were treated with methadone in the individual clinical studies, combining the data from the three studies conducted in this indication enabled a better assessment of the effect of methadone use on lubiprostone treatment response. A limitation of this study is the inherent bias associated with any post hoc analysis.
In conclusion, the phase 3 study described here did not meet its primary efficacy end point. However, pooled analysis from all three pivotal studies in the OIC development program, which was stratified by use of methadone, indicates that lubiprostone is an effective and well-tolerated treatment in patients with OIC taking the most commonly prescribed opioids for chronic noncancer pain. 
